187 related articles for article (PubMed ID: 32371897)
1. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
[TBL] [Abstract][Full Text] [Related]
2. Allotopic mRNA localization to the mitochondrial surface rescues respiratory chain defects in fibroblasts harboring mitochondrial DNA mutations affecting complex I or v subunits.
Bonnet C; Kaltimbacher V; Ellouze S; Augustin S; Bénit P; Forster V; Rustin P; Sahel JA; Corral-Debrinski M
Rejuvenation Res; 2007 Jun; 10(2):127-44. PubMed ID: 17518546
[TBL] [Abstract][Full Text] [Related]
3. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
4. [MITO-Porter; a cutting-edge technology for mitochondrial gene therapy].
Furukawa R; Yamada Y; Harashima H
Yakugaku Zasshi; 2012; 132(12):1389-98. PubMed ID: 23208046
[TBL] [Abstract][Full Text] [Related]
5. An analysis of membrane fusion between mitochondrial double membranes and MITO-Porter, mitochondrial fusogenic vesicles.
Yamada Y; Fukuda Y; Harashima H
Mitochondrion; 2015 Sep; 24():50-5. PubMed ID: 26188112
[TBL] [Abstract][Full Text] [Related]
6. Multisystem mitochondrial diseases due to mutations in mtDNA-encoded subunits of complex I.
Danhelovska T; Kolarova H; Zeman J; Hansikova H; Vaneckova M; Lambert L; Kucerova-Vidrova V; Berankova K; Honzik T; Tesarova M
BMC Pediatr; 2020 Jan; 20(1):41. PubMed ID: 31996177
[TBL] [Abstract][Full Text] [Related]
7. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes.
Yasuzaki Y; Yamada Y; Harashima H
Biochem Biophys Res Commun; 2010 Jun; 397(2):181-6. PubMed ID: 20580633
[TBL] [Abstract][Full Text] [Related]
9. A catalytic defect in mitochondrial respiratory chain complex I due to a mutation in NDUFS2 in a patient with Leigh syndrome.
Ngu LH; Nijtmans LG; Distelmaier F; Venselaar H; van Emst-de Vries SE; van den Brand MA; Stoltenborg BJ; Wintjes LT; Willems PH; van den Heuvel LP; Smeitink JA; Rodenburg RJ
Biochim Biophys Acta; 2012 Feb; 1822(2):168-75. PubMed ID: 22036843
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Mitochondrial Genome Via a MITO-Porter : Evaluation of mtDNA and mtRNA Levels and Mitochondrial Function.
Yamada Y; Harashima H
Methods Mol Biol; 2021; 2275():227-245. PubMed ID: 34118041
[TBL] [Abstract][Full Text] [Related]
11. Complex I deficiency related to T10158C mutation ND3 gene: A further definition of the clinical spectrum.
Grosso S; Carluccio MA; Cardaioli E; Cerase A; Malandrini A; Romano C; Federico A; Dotti MT
Brain Dev; 2017 Mar; 39(3):261-265. PubMed ID: 27742419
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel MT-ND3 variant and restoring mitochondrial function by allotopic expression of MT-ND3 gene.
Borna NN; Kishita Y; Shimura M; Murayama K; Ohtake A; Okazaki Y
Mitochondrion; 2024 May; 76():101858. PubMed ID: 38437941
[TBL] [Abstract][Full Text] [Related]
14. Leigh disease presenting in utero due to a novel missense mutation in the mitochondrial DNA-ND3.
Leshinsky-Silver E; Lev D; Malinger G; Shapira D; Cohen S; Lerman-Sagie T; Saada A
Mol Genet Metab; 2010 May; 100(1):65-70. PubMed ID: 20202874
[TBL] [Abstract][Full Text] [Related]
15. [Development of the MITO-porter, a nano device for mitochondrial drug delivery via membrane fusion].
Yamada Y
Yakugaku Zasshi; 2014; 134(11):1143-55. PubMed ID: 25366911
[TBL] [Abstract][Full Text] [Related]
16. Long survival in patients with leigh syndrome and the m.10191T>C mutation in MT-ND3 : a case report and review of the literature.
Levy RJ; Ríos PG; Akman HO; Sciacco M; Vivo DC; DiMauro S
J Child Neurol; 2014 Oct; 29(10):NP105-10. PubMed ID: 24284231
[TBL] [Abstract][Full Text] [Related]
17. MITO-Porter for Mitochondrial Delivery and Mitochondrial Functional Analysis.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2017; 240():457-472. PubMed ID: 27830347
[TBL] [Abstract][Full Text] [Related]
18. A method for screening mitochondrial fusogenic envelopes for use in mitochondrial drug delivery.
Yamada Y; Harashima H
Methods Mol Biol; 2014; 1141():57-66. PubMed ID: 24567130
[TBL] [Abstract][Full Text] [Related]
19. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery.
Yamada Y; Furukawa R; Yasuzaki Y; Harashima H
Mol Ther; 2011 Aug; 19(8):1449-56. PubMed ID: 21694702
[TBL] [Abstract][Full Text] [Related]
20. A high mutation load of m.14597A>G in MT-ND6 causes Leigh syndrome.
Kishita Y; Ishikawa K; Nakada K; Hayashi JI; Fushimi T; Shimura M; Kohda M; Ohtake A; Murayama K; Okazaki Y
Sci Rep; 2021 May; 11(1):11123. PubMed ID: 34045482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
